Published in Eur J Clin Pharmacol on April 04, 2017
Leukotrienes and sex: strange bedfellows? J Clin Invest (2017) 0.75
Role of the Cysteinyl Leukotrienes in the Pathogenesis and Progression of Cardiovascular Diseases. Mediators Inflamm (2017) 0.75
Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem (2000) 8.86
Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med (2011) 6.89
The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet (2004) 5.31
Pro-resolving lipid mediators are leads for resolution physiology. Nature (2014) 4.15
Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med (2004) 4.06
The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med (2004) 3.34
Comparison of the effects of intravenous and oral montelukast on airway function: a double blind, placebo controlled, three period, crossover study in asthmatic patients. Thorax (2000) 2.74
Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA (1998) 2.60
Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med (1999) 2.53
Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. Chem Rev (2011) 2.40
Leukotrienes C4 and D4 stimulate human endothelial cells to synthesize platelet-activating factor and bind neutrophils. Proc Natl Acad Sci U S A (1986) 2.18
Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci U S A (2003) 2.17
The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med (1990) 2.03
Allergen challenge of lung tissue from asthmatics elicits bronchial contraction that correlates with the release of leukotrienes C4, D4, and E4. Proc Natl Acad Sci U S A (1983) 2.01
Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA (2005) 1.94
Leukotriene-receptor antagonists. Lancet (1999) 1.93
The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma. Chest (2001) 1.85
Upregulation of the 5-lipoxygenase pathway in human aortic valves correlates with severity of stenosis and leads to leukotriene-induced effects on valvular myofibroblasts. Circulation (2011) 1.78
Aspirin-triggered lipoxin A4 blocks reactive oxygen species generation in endothelial cells: a novel antioxidative mechanism. Thromb Haemost (2007) 1.74
Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells. Am J Physiol Cell Physiol (2005) 1.74
Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J Immunol (2004) 1.73
Effects of leukotriene D on the airways in asthma. N Engl J Med (1983) 1.69
Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug Discov (2005) 1.69
Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. J Biol Chem (1999) 1.64
Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging (2010) 1.57
Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J (1991) 1.54
Targeted gene disruption reveals the role of cysteinyl leukotriene 1 receptor in the enhanced vascular permeability of mice undergoing acute inflammatory responses. J Biol Chem (2002) 1.43
Anti-inflammatory effects of montelukast in mild cystic fibrosis. Ann Allergy Asthma Immunol (2002) 1.41
Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. Eur Respir J (1998) 1.39
Leukotriene B4: metabolism and signal transduction. Arch Biochem Biophys (2001) 1.34
Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends. Med Res Rev (2007) 1.27
Novel lipid mediator regulators of endothelial cell proliferation and migration: aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4). J Pharmacol Exp Ther (2002) 1.27
Leukotriene D4: a potent coronary artery vasoconstrictor associated with impaired ventricular contraction. Science (1982) 1.23
Bronchoconstrictor effects of leukotriene E4 in normal and asthmatic subjects. Am Rev Respir Dis (1987) 1.22
Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. J Allergy Clin Immunol (2012) 1.20
Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation. Circulation (1992) 1.18
Adult asthma and risk of coronary heart disease, cerebrovascular disease, and heart failure: a prospective study of 2 matched cohorts. Am J Epidemiol (2012) 1.17
The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease. Cardiovasc Res (2010) 1.15
5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation. Circ Res (2007) 1.11
International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions. Pharmacol Rev (2011) 1.10
Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls. N Engl J Med (1986) 1.10
The 5-lipoxygenase pathway in arterial wall biology and atherosclerosis. Biochim Biophys Acta (2005) 1.09
Resolvin E1 regulates adenosine diphosphate activation of human platelets. Arterioscler Thromb Vasc Biol (2010) 1.09
Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice. Eur J Clin Invest (2006) 1.09
Asthma and leukotrienes: antileukotrienes as novel anti-asthmatic drugs. J Intern Med (1999) 1.09
Short-term effects of montelukast in stable patients with moderate to severe COPD. Respir Med (2005) 1.08
Molecular and functional aspects of human cysteinyl leukotriene receptors. Pharmacol Res (2004) 1.04
Leukotrienes as mediators of asthma. Pulm Pharmacol Ther (2001) 1.04
Antileukotrienes in the treatment of asthma. Ann Intern Med (1997) 1.04
Production of leukotrienes in a model of focal cerebral ischaemia in the rat. Br J Pharmacol (2001) 1.03
Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7. Br J Pharmacol (2014) 1.03
Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev (2012) 1.03
A selective cysteinyl leukotriene receptor 2 antagonist blocks myocardial ischemia/reperfusion injury and vascular permeability in mice. J Pharmacol Exp Ther (2011) 1.02
Leukotriene signaling in atherosclerosis and ischemia. Cardiovasc Drugs Ther (2008) 1.00
Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol (2000) 0.99
Montelukast protects against renal ischemia/reperfusion injury in rats. Pharmacol Res (2006) 0.99
Inhibitors of the 5-lipoxygenase pathway in atherosclerosis. Curr Pharm Des (2009) 0.99
Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr Pulmonol (2009) 0.99
Peptido-leukotrienes are potent agonists of von Willebrand factor secretion and P-selectin surface expression in human umbilical vein endothelial cells. Circulation (1995) 0.98
Activation of CysLT receptors induces astrocyte proliferation and death after oxygen-glucose deprivation. Glia (2008) 0.97
A novel peptide agonist of formyl-peptide receptor-like 1 (ALX) displays anti-inflammatory and cardioprotective effects. J Pharmacol Exp Ther (2008) 0.95
Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. Respir Med (2006) 0.95
Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT(2)) receptor. Br J Pharmacol (2010) 0.95
Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol (2002) 0.95
Leukotrienes and atherosclerosis. Curr Drug Targets (2010) 0.95
A second cysteinyl leukotriene receptor in human lung. J Pharmacol Exp Ther (1992) 0.94
Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice. Pharmacology (2004) 0.94
Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke. Med Res Rev (2012) 0.94
Increased expression of cysteinyl leukotriene receptor-1 in the brain mediates neuronal damage and astrogliosis after focal cerebral ischemia in rats. Neuroscience (2006) 0.93
Genetic and pharmacological inhibition of the 5-lipoxygenase/leukotriene pathway in atherosclerotic lesion development in ApoE deficient mice. Atherosclerosis (2008) 0.92
Effect of montelukast and MK-886 on hepatic ischemia-reperfusion injury in rats. J Surg Res (2008) 0.92
Cysteinyl leukotrienes induce P-selectin expression in human endothelial cells via a non-CysLT1 receptor-mediated mechanism. J Pharmacol Exp Ther (1997) 0.92
Cysteinyl-leukotriene receptor antagonist montelukast decreases blood-brain barrier permeability but does not prevent oedema formation in traumatic brain injury. Brain Inj (2009) 0.91
Long-term montelukast therapy in moderate to severe COPD--a preliminary observation. Respir Med (2004) 0.91
Protective potential of montelukast against hepatic ischemia/reperfusion injury in rats. J Surg Res (2008) 0.91
Pranlukast, a cysteinyl leukotriene receptor-1 antagonist, protects against chronic ischemic brain injury and inhibits the glial scar formation in mice. Brain Res (2005) 0.91
Effect of montelukast on nuclear factor kappaB activation and proinflammatory molecules. Ann Allergy Asthma Immunol (2005) 0.91
Leukotriene receptors: crucial components in vascular inflammation. ScientificWorldJournal (2007) 0.91
Cysteinyl-leukotrienes receptor activation in brain inflammatory reactions and cerebral edema formation: a role for transcellular biosynthesis of cysteinyl-leukotrienes. FASEB J (2004) 0.90
Treatment of inflammatory diseases by selective eicosanoid inhibition: a double-edged sword? Trends Pharmacol Sci (2007) 0.90
Pranlukast attenuates ischemia-like injury in endothelial cells via inhibiting reactive oxygen species production and nuclear factor-kappaB activation. J Cardiovasc Pharmacol (2009) 0.90
Leukotrienes: role in cardiovascular physiology. Cardiovasc Clin (1987) 0.89
Cysteinyl-leukotriene receptor antagonists: present situation and future opportunities. Curr Med Chem (2006) 0.89
Montelukast for the treatment of asthma in the adult population. Expert Opin Pharmacother (2011) 0.89
Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis. J Pharmacol Exp Ther (2006) 0.88
Multidrug resistance protein-1 affects oxidative stress, endothelial dysfunction, and atherogenesis via leukotriene C4 export. Circulation (2008) 0.88
Cysteinyl leukotrienes regulate endothelial cell inflammatory and proliferative signals through CysLT₂ and CysLT₁ receptors. Sci Rep (2013) 0.88
Efficacy of iloprost and montelukast combination on spinal cord ischemia/reperfusion injury in a rat model. J Cardiothorac Surg (2013) 0.88
Brain eicosanoid levels in spontaneously hypertensive rats after ischemia with reperfusion: leukotriene C4 as a possible cause of cerebral edema. Stroke (1988) 0.88
Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats. J Pharm Pharmacol (2011) 0.88
Benefit-risk assessment of antileukotrienes in the management of asthma. Drug Saf (2003) 0.87
Myocardial salvage induced by REV-5901: an inhibitor and antagonist of the leukotrienes. J Cardiovasc Pharmacol (1987) 0.86
The effect of montelukast on atherogenesis in apoE/LDLR-double knockout mice. J Physiol Pharmacol (2008) 0.86
Synthesis of cysteinyl leukotrienes in human endothelial cells: subcellular localization and autocrine signaling through the CysLT2 receptor. FASEB J (2011) 0.85
The efficacy and tolerability of intravenous montelukast in acute asthma exacerbations in Japanese patients. J Asthma (2012) 0.85
BAY u9773, a novel antagonist of cysteinyl-leukotrienes with activity against two receptor subtypes. Eur J Pharmacol (1994) 0.85
Spatio-temporal expression of cysteinyl leukotriene receptor-2 mRNA in rat brain after focal cerebral ischemia. Neurosci Lett (2006) 0.84
CysLT2 receptor-mediated AQP4 up-regulation is involved in ischemic-like injury through activation of ERK and p38 MAPK in rat astrocytes. Life Sci (2010) 0.84